Article Text

Download PDFPDF

E-058 Safety and outcomes of intra-arterial tissue plasminogen activator as an adjunctive technique for distal embolization – insights from STAR
  1. E Almallouhi1,
  2. S Al kasab2,
  3. A Alawieh2,
  4. M Psychogios3,
  5. A Arthur4,
  6. J Kim5,
  7. R De Leacy6,
  8. A Rai7,
  9. S Keyrouz8,
  10. K Fargen9,
  11. T Dumont10,
  12. P Kan11,
  13. R Starke12,
  14. A Spiotta2
  1. 1Medical University of South Carolina, Charleston, SC
  2. 2Neurosurgery, Medical University of South Carolina, Charleston, SC
  3. 3Neuroradiology, Universitätsspital Basel, Basel, SWITZERLAND
  4. 4Neurosurgery, University of Tennessee Health Science Center, Memphis, TN
  5. 5Chonnam Natl Univ Hosp, Kwangju, Korea, Republic of
  6. 6Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY
  7. 7West Virginia University, Morgantown, WV
  8. 8Washington University in St Louis, St Louis, MO
  9. 9Wake Forest University, Winston-Salem, NC
  10. 10University of Arizona, Tucson, AZ
  11. 11Baylor University, Houston, TX
  12. 12Neurosurgery, Medical University of South Carolina, Miami, FL


Introduction Early studies have shown that using intra-arterial thrombolysis is effective in achieving recanalization in patients with acute ischemic stroke. However, the using intraarterial thrombolysis was associated with a high rate of symptomatic hemorrhagic transformation (sICH). In current practice time, intra-arterial thrombolysis using tissue plasminogen activator (IA-tPA) can be used as an adjunctive technique in the setting of persistent distal occlusion during mechanical thrombectomy (MT).

Methods We used data from the Stroke Thrombectomy and Aneurysm Registry (STAR), which included the prospectively maintained databases from 28 thrombectomy-capable stroke centers in the US, Europe, and Asia. We included only consecutive patients who received MT using second generation thrombectomy devices. Then, we identified patients who received 5–10 mg of IA-tPA injected directly to the target vessel because of persistent distal occlusion during MT. We collected the baseline characteristics, procedural metrics, rate of sICH, and long-term functional outcomes. We estimated a Generalized Linear Model (GLM) with logit link to assess predictors of sICH, successful recanalization (Thrombolysis in Cerebral Infarction score≥2b), and favorable 90-day functional outcomes (modified Rankin scale 0–2 at 90-day).

Results A total of 154 patients received IA-tPA out of 1608 thrombectomy patients who were included in this analysis. Median age was 68 (IQR 57–76) years; 79 (51.3%) were females; 97 (63%) were white. There was no difference in stroke severity measured by the National Institute of Health stroke scale (NIHSS) (17 vs. 15, P=0.079) or Alberta Stroke Program Early CT (ASPECT) score (9 vs. 9, P=0.16) between patients in the IA-tPA group compared to the non-IA-tPA group, respectively. In addition, no difference was noted in the prevalence of stroke risk factors (hypertension, diabetes, atrial fibrillation, prior stroke) between both groups. IA-tPA group had less patients who have received IV-tPA (33.8% vs. 54.9%, P<0.001) and longer onset-to-groin time (281 vs. 249 min, P=0.003) (table 1). Patients in the IA-tPA group achieved similar rates of successful recanalization (73.4% vs. 74.6%, P=0.736) and favorable functional outcomes (40.9% vs. 40.8%, P=0.976). On multivariate analysis, using IA-tPA was not independently associated with sICH (RR 0.761, 95% CI 0.323–1.798, P=0.535), successful recanalization (OR 0.888, 95% CI 0.589–1.339, P=0.572), or favorable functional outcomes (OR 1.065, 95% CI 0.72–1.575, P=0.752).

Abstract E-058 Table 1

Conclusion The use of IA-tPA as an adjunctive treatment to mechanical thrombectomy due to persistent distal occlusion did not result in a higher rate of successful recanalization, 90-day functional independence, or sICH.

Disclosures E. Almallouhi: None. S. Al kasab: None. A. Alawieh: None. M. Psychogios: None. A. Arthur: 1; C; Microvention, Penumbra, and Siemens;. 2; C; Balt, Johnson and Johnson, Leica, Medtronic, Microvention, Penumbra, Scientia, Siemens, and Stryker. 4; C; Bendit, Cerebrotech, Endostream, Magneto, Marblehead, Neurogami, Serenity, Synchron, Triad Medical and Vascular Simulations. J. Kim: None. R. De Leacy: 2; C; Cerenovus, Imperative Care and Siemens. A. Rai: None. S. Keyrouz: None. K. Fargen: None. T. Dumont: None. P. Kan: None. R. Starke: 2; C; Penumbra, Abbott, Medtronic, InNeuroCo and Cerenovus. A. Spiotta: 1; C; Penumbra. 2; C; Penumbra, Stryker, Cerenovus, Terumo.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.